Published in final edited form as:

Int J Radiat Oncol Biol Phys. 2013 February 1; 85(2): 444–450. doi:10.1016/j.ijrobp.2012.04.043.

Predicting Radiation Pneumonitis after Chemoradiotherapy for Lung Cancer: An International Individual Patient Data Meta-analysis

David A. Palma, MD, MSc, PhD¹, Suresh Senan, MRCP, FRCR, PhD², Kayoko Tsujino, MD³, Robert B Barriger, MD⁴, Ramesh Rengan, MD, PhD⁵, Marta Moreno, MD⁶, Jeffrey D. Bradley, MD⁷, Tae Hyun Kim, MD⁸, Sara Ramella, MD⁹, Lawrence B. Marks, MD¹⁰, Luigi De Petris, MD, PhD¹¹, Larry Stitt, MSc¹², and George Rodrigues, MD, MSc^{1,12}

¹Department of Radiation Oncology, London Regional Cancer Program, London, Canada

²Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands

³Department of Radiation Oncology, Hyogo Cancer Center, Hyogo, Japan ⁴Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA

⁵Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

⁶Departament of Oncology, Radiation Oncology Division, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain ⁷Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri ⁸Center for Proton Therapy, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea ⁹Radiotherapy Unit, Campus Bio-Medico University, Rome, Italy ¹⁰Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina, USA ¹¹Department of Oncology, Radiumhemmet, Karolinska University Hospital Solna, Stockholm, Sweden ¹²Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada

Abstract

Background—Radiation pneumonitis is a dose-limiting toxicity for patients undergoing concurrent chemoradiation therapy (CCRT) for non-small cell lung cancer (NSCLC). We performed an individual patient data meta-analysis to determine factors predictive of clinically significant pneumonitis.

Methods—After a systematic review of the literature, data was obtained on 836 patients who underwent CCRT in Europe, North America and Asia. Patients were randomly divided into training and validation sets (2/3 vs. 1/3 of patients). Factors predictive of symptomatic pneumonitis (grade 2 by one of several scoring systems) or fatal pneumonitis were evaluated using logistic regression. Recursive partitioning analysis (RPA) was used to define risk groups.

© 2012 Elsevier Inc. All rights reserved.

Corresponding Author: Dr. David Palma, London Regional Cancer Program, 790 Commissioners Rd. London, Canada, N6A4L6, Phone: +1-519-685-8500, Fax: +1-519-685-8627. david.palma@uwo.ca.

Conflict of Interest Statement

Dr. Palma was the recipient of the 2009 Canadian Association of Radiation Oncologists' Elekta Research Fellowship. Dr. Senan has received research funding from Sanofi-Aventis, speaking honoraria from Varian Medical Systems Inc, has a departmental master research agreement with Varian Medical Systems Inc., and is a member of the trial management group for the phase III PROCLAIM study, which is sponsored by Eli Lilly.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Results—The median radiotherapy dose was 60 Gy, and median follow-up was 2.3 years. Most patients received concurrent cisplatin/etoposide (38%) or carboplatin/paclitaxel (26%). The overall rate of symptomatic pneumonitis was 29.8% (n=249), with fatal pneumonitis in 1.9% (n=16). In the training set, factors predictive of symptomatic pneumonitis were lung volume receiving 20 Gy (V_{20}) [OR:1.03 per 1% increase, $p=0.008$], and carboplatin/paclitaxel chemotherapy [OR:3.33, $p<0.001$], with a trend for age [OR: 1.24 per decade, $p=0.09$]; the model remained predictive in the validation set with good discrimination in both datasets (c -statistic >0.65). On RPA, the highest risk of pneumonitis ($>50\%$) was in patients >65 years of age receiving carboplatin/paclitaxel. Predictors of fatal pneumonitis were daily dose >2 Gy, V_{20} , and lower-lobe tumor location.

Conclusions—Several treatment-related risk factors predict the development of symptomatic pneumonitis, and elderly patients who undergo CCRT with carboplatin-paclitaxel chemotherapy are at highest risk. Fatal pneumonitis, although uncommon, is related to dosimetric factors and tumor location.

Keywords

Non-small cell lung cancer; radiotherapy; chemotherapy; pneumonitis

INTRODUCTION

Concurrent chemoradiotherapy (CCRT) is the standard of care in patients presenting with a locally advanced non-small cell lung cancer (NSCLC), as the role of surgery in patients with documented mediastinal nodal disease remains controversial (1). Compared to sequential chemotherapy and radiation therapy, CCRT results in improved survival outcomes, at the cost of increased acute toxicity (1). Currently, a number of different radiation schedules and chemotherapy combinations are in clinical use for CCRT.

Symptomatic radiation pneumonitis is a clinically important toxicity, occurring in 15–40% of patients receiving CCRT for NSCLC (2). The risk of pneumonitis limits the radiotherapy dose that can be safely delivered and the size of the volumes treated. Radiation pneumonitis can limit quality of life, and uncommonly result in oxygen dependence or death (2).

Several studies have identified relationships between baseline patient- or dose-related factors and rates of radiation pneumonitis (2), but predictive models have not been widely implemented for several reasons: many earlier studies included heterogeneous groups of patients not necessarily applicable to modern NSCLC treatment (i.e. patients treated without chemotherapy, with older radiotherapy techniques, or for non-lung malignancies); correlations between baseline variables and pneumonitis outcomes are generally weak; and results are rarely validated in separate datasets (2, 3). As a result, the ability of a physician to predict the risk of clinically significant pneumonitis for any particular patient is limited.

Recently, the Quantitative Analysis of Normal Tissue Effects in Clinic (QUANTEC) project reviewed more than 70 published articles to provide normal-tissue dose constraints for radiation-induced lung injury (4). Due to inconsistent relationships between patient- and treatment-related factors and pneumonitis risk, QUANTEC recommended the pooling of individual patient data from many institutions to undertake meta-analyses in an effort to overcome some of the limitations of previous studies. Consequently, we undertook a collaborative project entitled “Systematic analysis of toxicity after radical irradiation: pneumonitis and esophagitis” (STRIPE) to combine patient-level data from several institutions worldwide. The goal of this first component of the STRIPE project was to develop and validate a predictive model for radiation pneumonitis in patients receiving modern CCRT for the treatment of locally-advanced NSCLC.

METHODS

A systematic review was conducted to identify articles published in MEDLINE between 1993 and August 2010 reporting on dosimetric predictors of radiation pneumonitis after CCRT for non-small cell lung cancer. Reference lists from candidate articles were hand-searched for additional articles, and international experts were individually contacted to identify additional published or unpublished datasets. Authors were then contacted and invited to submit datasets with individual patient data, whether published or unpublished. The search strategy and results are shown in Online Appendix 1. Institutional Research Ethics Board approval was obtained.

Patients were included in the analysis if they were treated with concurrent chemoradiotherapy for NSCLC with radical intent. Patients who did not receive full-doses of radiation due to the development of toxicity *during* treatment remained included. Two-dimensional radiotherapy was not allowed; radiotherapy had to be delivered as three-dimensional conformal radiation therapy or intensity modulated radiation therapy. Patients who received either induction (or neoadjuvant, prior to CCRT) or adjuvant (after CCRT) chemotherapy were permitted. Patients were excluded from the analysis if the histology was small-cell lung cancer, if they had stage IV disease, or if they underwent surgical resection. Patients were staged according to the American Joint Committee on Cancer (AJCC) sixth edition.

The primary endpoint of this study was symptomatic radiation pneumonitis, defined as: Grade 2 or higher as per the Common Terminology Criteria for Adverse Events [CTC-AE] version 3.0 (i.e. symptomatic), and/or requiring steroids. In individual datasets, the scoring systems used including CTC-AE versions 2 and 3, the Radiation Therapy and Oncology Group (RTOG) scale, the Southwest Oncology Group scale, and two in-house scales. In each of these scoring systems, any patient scored as having Grade 2 pneumonitis equivalent was scored as meeting the primary endpoint in this current study. The timing of pneumonitis was not widely available; therefore actuarial rates were not reported.

The volume of lung considered as the organ at risk (OAR) was defined as the total lung volume minus the gross tumor volume [i.e. total lung – GTV]. For patients whose V₂₀ data was only available using the definition of lung OAR as total lung minus planning target volume [i.e. total lung – PTV], the corresponding “total lung – GTV” values were calculated by imputation based on a linear relationship between the two definitions, which was found to be a good fit with $r=0.988$. The resulting equation for V₂₀ was: $V_{20}(\text{lung-GTV}) = 3.02528 + 1.00823 * V_{20}(\text{lung-PTV})$; indicating that a patient with a V₂₀ of 30% using the lung-PTV definition would have a V₂₀ of 33.3% using the lung-GTV definition; a similar imputation was done for mean lung dose (MLD). Six patients had only data with the lung OAR defined as the total lung volume minus clinical target volume [i.e. total lung – CTV], and these patients were excluded as there was insufficient data for imputation. Performance status was scored by different institutions using either the Eastern Cooperative Oncology Group (ECOG) scale or the Karnofsky Performance Scale (KPS). In order to combine these into a single variable, patients were classified patients as having “Good performance status” (ECOG 0–1 or KPS 70–100) or “Poor performance status” (ECOG >1 or KPS <70).

For the endpoint of symptomatic pneumonitis, patients were randomly divided into a training set (two-thirds of patients) and a validation set (one-third of patients) using a random number generator, without stratification. In the training set, logistic regression was used to determine factors predictive of pneumonitis. Any variables associated with the development of pneumonitis on univariable analysis (with a cutoff alpha of 0.10) with data available for at least two-thirds of patients were considered for entry into a stepwise

multivariable model with entry and removal allowed at the 10% level of significance. Data was required on two-thirds of patients since patients with missing data are excluded from multivariable logistic modeling. The performance of the multivariable model was then evaluated using the validation set.

A recursive partitioning analysis (RPA) was then constructed in the training set to stratify patients into risk groups. This RPA is independent of the multivariable analysis described above. The classification method of recursive partitioning was used, with a minimum number of observations per node of 20 before a split was considered, and a default number of minimum observations of 7 in a terminal node. This RPA stratification was then re-tested on the validation set. RPA was done independently of the multivariable analysis. RPA cutoffs were rounded to increase clinical utility.

For the endpoint of fatal pneumonitis, there were insufficient numbers of events to allow for modeling with a training and validation set, and therefore the dataset was analyzed as a whole. For this endpoint, logistic regression was used for continuous variables and Fisher's exact test used for categorical variables.

Survival estimates were calculated using the Kaplan-Meier method, and median follow-up was calculated using the reverse Kaplan-Meier estimate. All statistical tests were two-sided with a $p < 0.05$ indicative of statistical significance, done using SAS 9.2 (Cary, North Carolina, USA) or R 2.13 (Vienna, Austria).

RESULTS

Data was available on 836 patients from 12 different sources (Table 1), all previously reported in whole or in part, including 10 manuscripts (3, 5–13) and 2 abstracts (14, 15), some of which provided updated datasets. The final composite dataset included patients treated at centers in Europe ($n=297$, 36%), North America ($n=286$, 34%) and Asia ($n=253$, 30%). Baseline clinical characteristics are shown in Table 2. The median total dose delivered was 60 Gy, most often in fractionated doses of 2 Gy per day (73%), 1.8 Gy per day (13%) or 1.2 Gy twice daily (8%). Median follow-up was 2.3 years. There were 415 deaths in the cohort during the follow-up period, with a median overall survival (OS) of 1.7 years, 2-year OS of 44% and 5-year OS of 22%. The overall rate of symptomatic pneumonitis was 29.8% ($n=249$).

Most patients received concurrent cisplatin/etoposide (38%) or carboplatin/paclitaxel (26%). 'Other' chemotherapy regimens included: cisplatin doublets (24%) [with docetaxel (11%), vinorelbine (7%), gemcitabine (2%) or other drugs (4%)], carboplatin doublets (5%), or gemcitabine (6%). Elderly patients (age >65) were more likely to receive 'other' types of chemotherapy (delivered to 43% of elderly patients vs. 32% of younger patients; $p=0.02$), corresponding to less use of cisplatin-etoposide in elderly patients (32% vs. 42%, respectively), with similar rates of use of carboplatin-paclitaxel (25% vs. 26%, respectively).

Results from the univariable analysis and multivariable analysis on the training dataset ($n=557$) are shown in Table 3. On multivariable analysis, factors predictive of development of radiation pneumonitis were V_{20} [odds ratio (OR) 1.03 per 1% increase in V_{20} , $p=0.008$], chemotherapy regimen [OR for carboplatin/paclitaxel 3.33, relative to cisplatin-etoposide; $p<0.001$], and with a trend toward significance for advanced age [OR per 10-yr increase 1.24, 95% CI 0.97–1.59, $p=0.09$]. The c-statistic for this model was 0.66, indicating good discrimination.

Assessment of the model on the validation set ($n=279$) is shown in Table 4, with very similar results as in the training set: chemotherapy and V_{20} significantly predicted

pneumonitis risk (both $p < 0.001$) with a trend toward significance for age ($p = 0.089$), with similar ORs as in the training set, and the c-statistic of 0.69 confirmed good discrimination. The risk of pneumonitis based on cutoffs of V_{20} for the whole cohort combined is shown in Table 5.

Results of the STRIPE recursive partitioning analysis are shown in Figure 1. Based on chemotherapy regimen, age > 65 , V_{20} , and MLD, patients can be divided into a high-risk group (patients > 65 years of age receiving carboplatin-paclitaxel); two intermediate-risk groups; and two low-risk groups. The differences in pneumonitis rates between these groups was statistically significant ($p < 0.001$). Application of the categories formed by the RPA to the validation set was consistent with those by the training data set. There was a strong correlation ($r^2 = 0.902$) between the pneumonitis rates in the training and validation sets in each of the risk categories, and the differences in pneumonitis rates between the risk groups remained statistically significant.

Fatal pneumonitis occurred in sixteen patients (1.9%), an insufficient number to allow for detailed modeling with a training and validation set, or construction of a RPA model, and therefore the dataset was analyzed as a whole. Total daily dose greater than 2 Gy (7% if > 2 Gy vs. 1.5% if ≤ 2 Gy; $p = 0.01$), V_{20} (OR 1.09 per 1% increase, $p = 0.044$), and tumor location (1% for upper lobe, 0% for middle lobe, and 5% for lower lobe, $p = 0.007$) were found to be associated with fatal pneumonitis.

DISCUSSION

The onset of radiation pneumonitis after radical CCRT for NSCLC is associated with significant morbidity and occasionally mortality. To our knowledge, this is the largest study evaluating predictors of radiation pneumonitis following CCRT for lung cancer; it is one of very few studies employing separate training and validation datasets; and importantly it identifies several treatment-related variables that can be used to optimize the therapeutic ratio in patients undergoing CCRT. A key finding is the suggestion that age, dosimetric parameters, and choice of chemotherapy regimen can allow for significant stratification of radiation pneumonitis risk. Although fatal pneumonitis is uncommon, it was associated with large daily doses, high V_{20} values, and lower-lobe tumors. As a result, efforts to minimize V_{20} and fraction size are warranted in the setting of concurrent CCRT.

The findings of this study are congruent with the existing literature regarding pneumonitis risk, and extend those findings in several important ways. Increasing age and delivery of concurrent taxane-based chemotherapy have been separately identified as risk factors for radiation pneumonitis (4, 16, 17). Taxanes are potent radiosensitizers when given concurrently with radiotherapy (16, 17). A recent study of a cohort of lung cancer patients predominantly treated with carboplatin-paclitaxel CCRT found that both chemotherapy use and age were associated with large increases in pneumonitis risk: the incidence of pneumonitis in patients receiving chemotherapy was 63% (vs. 16% in patients not receiving chemotherapy) with a trend toward increased risk in patients receiving carboplatin-paclitaxel specifically. Pneumonitis occurred in 77% of patients aged 61–70, with lower rates in patients of different ages (16). These data support the finding that the choice of chemotherapy regimen plays an important role in pneumonitis risk, particularly in the elderly.

Several chemotherapy regimens are available for concurrent CCRT, and the choice of chemotherapy regimen is the subject of some controversy. Several platinum-based chemotherapy regimens have demonstrated encouraging clinical outcomes (1). In the context of palliative chemotherapy, a meta-analysis has demonstrated that cisplatin is a more

active first-line treatment against NSCLC than carboplatin: cisplatin achieves superior response rates, and in some subgroups improved survival (18).. The carboplatin-paclitaxel CCRT combination has been compared in a 3-arm randomized non-inferiority study against irinotecan-carboplatin and mitomycin-vindesine-cisplatin, with the latter considered the “standard” arm (19). All three arms received 60 Gy of radiation, but the “standard” arm incorporated split-course radiotherapy. Although survival outcomes were similar in all 3 arms, the non-inferiority endpoint was not met. Grade 3 or higher pneumonitis rates were not statistically different between the arms, whereas rates of grade 2 pneumonitis, or rates in elderly patients, were not reported. The National Comprehensive Cancer Network (NCCN) clinical practice guidelines recommend cisplatin-etoposide as the chemotherapy of choice for CCRT, with carboplatin-paclitaxel reserved for patients unable to tolerate full-dose cisplatin (1)., Although efficacy is of primary importance in choosing a chemotherapy regimen, avoidance of toxicity should also be a consideration.

The findings of this study must be considered in the context of its strengths and limitations. The large sample size that incorporates data from several institutions worldwide improves statistical power and the generalizability of the results, and the results have been validated in a separate dataset. However, several important limitations must be borne in mind. Adequate data was not available on some variables of interest, such as smoking status, co-morbidities, pulmonary function, and timing of radiation pneumonitis symptoms, and some data required imputation, which may have added a degree of imprecision. Some factors were not routinely captured at most institutions, including baseline patient factors (e.g. pulmonary function), biological factors (e.g. transforming growth factor beta levels), or more detailed dosimetric factors (e.g. normal tissue complication probabilities), which have been previously suggested as predictors of pneumonitis risk (2). Individual-level chemotherapy dosing was generally not available. There may also be differences between patients treated at different institutions that have not been captured, including differences in genetic risks of pneumonitis, treatment factors, or follow-up practices. Some of these unmeasured factors could have influenced the final results. These findings described may not be generalizable to patients with baseline characteristics or treatment parameters that differ from the population included herein, such as the patients aged >75, who are a minority of the patients included. These limitations underscore the importance of developing multi-institutional databases that can be populated prospectively, to allow for the construction of more detailed prediction models. Despite these limitations, the data presented here showing strata of risk based on V_{20} , MLD, and other clinical factors will allow clinicians to better predict and modify risk in patients undergoing CCRT.

The overall rates of radiation pneumonitis reported herein are in keeping with previously published CCRT studies, usually ranging between 15–40% for similar patient populations (2). One study of radiation dose escalation in combination with carboplatin-paclitaxel (RTOG 0117) reported a maximum tolerated dose of 74 Gy in 37 fractions in patients with a V_{20} 30%; at this dose level 33% of patients developed grade 2 or higher pulmonary toxicity. At a higher dose level (75.25 Gy in 35 fractions), 6/8 patients developed pulmonary toxicity, illustrating the dose-limiting effects of radiation pneumonitis (20). However, comparisons of pneumonitis rates across studies are limited by heterogeneity in patient populations, treatment, and outcome scoring.

Several previous studies have reported correlations between radiation dosimetric parameters and pneumonitis. V_{20} and MLD are frequently correlated with pneumonitis and are most commonly used in clinical practice, yet other variables have been shown to be predictive, including volume of lung receiving 5 Gy (V_5), 13 Gy (V_{13}), 25 Gy (V_{25}) and 30 Gy (V_{30}) (2). However, dosimetric variables tend to be very collinear (i.e. increasing V_{20} tends to lead to an increase in the other parameters), and therefore differences in predictive value

among different dosimetric variables may be small. The relative merit of decreasing one dosimetric variable (e.g. lowering the V_{20}) at the expense of another (e.g. raising the V_5) is unknown.

In conclusion, this study suggests that in patients undergoing concurrent chemoradiation therapy for NSCLC, pneumonitis risk is associated with the type of chemotherapy regimen, dosimetric parameters, and patient age. Fatal pneumonitis is uncommon, but is associated with large doses per fraction, large V_{20} , and lower-lobe tumors. Further research is needed to evaluate methods to mitigate pneumonitis risk in patients undergoing curative-intent CCRT.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Gabriel Bolt for assistance with literature review; Dr. Achilles Fakiris, Dr. Signe Friesland, Daniel Mullen, Eric Xanthopoulos, Michael Lawrence, Shiva Das, and Joke Bakker for assistance with data management. Supported by a Clinician-Scientist grant from the Ontario Institute for Cancer Research (D.A.P.), and NIH Grant CA69579 (L.B.M.).

References

1. NCCN Clinical Practice Guideline: Non-Small Cell Lung Cancer. Oct 1. 2011
2. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer--a systematic review. *Radiother Oncol*. 2004; 71:127–138. [PubMed: 15110445]
3. Bradley JD, Hope A, El Naqa I, et al. A Nomogram to Predict Radiation Pneumonitis, Derived From a Combined Analysis of RTOG 9311 and Institutional Data. *Int J Radiat Oncol Biol Phys*. 2007; 69:985–992. [PubMed: 17689035]
4. Marks LB, Bentzen SM, Deasy JO, et al. Radiation Dose–Volume Effects in the Lung. *Int J Radiat Oncol Biol Phys*. 2010; 76:S70–S76. [PubMed: 20171521]
5. Barriger RB, Fakiris AJ, Hanna N, et al. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatin and etoposide with or without consolidation docetaxel. *International journal of radiation oncology, biology, physics*. 2010; 78:1381–1386.
6. De Petris L, Lax I, Sirzen F, et al. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer. *Med Oncol*. 2005; 22:375–381. [PubMed: 16260855]
7. Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. *Radiology*. 2005; 235:208–215. [PubMed: 15703313]
8. Mao J, Kocak Z, Zhou S, et al. The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. *International journal of radiation oncology, biology, physics*. 2007; 67:1360–1369.
9. Moreno M, Aristu J, Ramos LI, et al. Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer. *Clin Transl Oncol*. 2007; 9:596–602. [PubMed: 17921108]
10. Phernambucq EC, Spoelstra FO, Verbakel WF, et al. Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. *Ann Oncol*. 2011; 22:132–138. [PubMed: 20595452]
11. Ramella S, Trodella L, Mineo TC, et al. Adding ipsilateral V_{20} and V_{30} to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with

- combined-modality therapy. *International journal of radiation oncology, biology, physics*. 2010; 76:110–115.
12. Senan S, Cardenal F, Vansteenkiste J, et al. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. *Ann Oncol*. 2011; 22:553–558. [PubMed: 20696676]
 13. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. *International journal of radiation oncology, biology, physics*. 2003; 55:110–115.
 14. Louie AV, Rodrigues G, Lee P, et al. Clinical and Technical Assessment of Respiratory Gated Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer. *International Journal of Radiation Oncology*Biography*Physics*. 2011; 81(2):S824.
 15. Orsamolu A, Xanthopoulos E, Fernandes A, et al. Predictive factors for symptomatic radiation pneumonitis in 293 consecutively treated non-small cell lung cancer (NSCLC) patients receiving definitive radiation therapy. *J Clin Oncol*. 2011; 29:2011. (suppl; abstr 7041). [PubMed: 21502544]
 16. Parashar B, Edwards A, Mehta R, et al. Chemotherapy Significantly Increases the Risk of Radiation Pneumonitis in Radiation Therapy of Advanced Lung Cancer. *Am J Clin Oncol*. 2011; 34:160–164. 110.1097/COC.1090b1013e3181d1096b1040f. [PubMed: 20498591]
 17. Onishi H, Kuriyama K, Yamaguchi M, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. *Lung Cancer*. 2003; 40:79–84. [PubMed: 12660011]
 18. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. *J Natl Cancer Inst*. 2007; 99:847–857. [PubMed: 17551145]
 19. Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. *J Clin Oncol*. 2010; 28:3739–3745. [PubMed: 20625120]
 20. Bradley JD, Moughan J, Graham MV, et al. A Phase I/II Radiation Dose Escalation Study With Concurrent Chemotherapy for Patients With Inoperable Stages I to III Non-Small-Cell Lung Cancer: Phase I Results of RTOG 0117. *Int J Radiat Oncol Biol Phys*. 2010; 77:367–372. [PubMed: 20457350]

Summary

Radiation pneumonitis is a dose-limiting toxicity for patients undergoing concurrent chemoradiation therapy (CCRT) for non-small cell lung cancer. This individual-patient data meta-analysis demonstrated that several treatment-related risk factors predict the development of symptomatic pneumonitis, and elderly patients who undergo CCRT with carboplatin-paclitaxel chemotherapy are at highest risk. Fatal pneumonitis was uncommon, but related to dosimetric factors and tumor location.

\$watermark-text

\$watermark-text

\$watermark-text

Figure 1. Recursive partitioning analysis of radiation pneumonitis risk in patients undergoing concurrent chemoradiation therapy (CCRT) for non-small cell lung cancer (NSCLC). Patients were randomly divided into a training set (T) and validation set (V). MLD: mean lung dose; V₂₀: volume of lung receiving 20 Gy.

Table 1

Sources of individual patient data

Institution	Number of Patients
Hyogo Medical Center, Japan	190
Indiana University School of Medicine, Indianapolis, USA	98
VU University Medical Center, Amsterdam, Netherlands	84
Pulmonart Multicenter Study	68
University of Pennsylvania, Philadelphia, USA	68
University of Navarra, Pamplona, Spain	67
Washington University School of Medicine, St. Louis, USA	64
National Cancer Center, Goyang, Korea	63
Campus Bio-Medico University, Rome, Italy	51
Duke University, Durham, USA	33
Karolinska University Hospital, Stockholm, Sweden	27
London Regional Cancer Program, London, Canada	23
Total	836

Table 2

Baseline clinical characteristics.

Variable	N with data available	Median (Range) or number (%)
Age	836	63 (26–86)
Sex	836	
Male		603 (72%)
Female		233 (28%)
Good Performance Status*	396	382 (96%)
Smoking History	511	462 (55%)
Histology	525	
Adenocarcinoma		155 (30%)
Large Cell		58 (11%)
Squamous		212 (40%)
NSCLC NOS		100 (19%)
Tumor Lobe Location	487	
Upper		327 (67%)
Middle		25 (5%)
Lower		135 (28%)
Tumor stage	836	
TX		36 (4%)
T1		90 (11%)
T2		245 (29%)
T3		196 (23%)
T4		269 (32%)
Nodal Stage	836	
NX		26 (3%)
N0		48 (6%)
N1		38 (5%)
N2		488 (58%)
N3		236 (28%)
Stage Grouping	836	
IB		1 (0.1%)
II		11 (1.3%)
III		824 (98.6%)
Neoadjuvant Chemotherapy	531	296 (56%)
Concurrent Chemotherapy	836	836 (100%)
Concurrent Chemotherapy Agents	633	
Cisplatin-Etoposide		243 (38%)
Carboplatin-Paclitaxel		164 (26%)

Variable	N with data available	Median (Range) or number (%)
Other **		226 (36%)
Adjuvant Chemotherapy	498	116 (23%)
Prescribed Radiation Dose (Gy)	834	60 (36–84)
Dose Per Fraction (Gy)	796	2 (1.2–2.15)
Lung volume receiving 5 Gy (%)	404	38 (14–100)
Lung volume receiving 20 Gy (%)	819	30 (7–78)
Mean Lung Dose (Gy)	759	17 (2–47)

IQR: interquartile range; NSCLC: non-small cell lung cancer; NOS: not otherwise specified

* defined as Eastern Cooperative Oncology Group Performance Status of 0–1 or Karnofsky performance status of 70.

** see text for details.

Table 3

Univariable and multivariable analysis of factors predictive of symptomatic radiation pneumonitis in the training dataset (n=557).

Factor	Univariable Analysis			Multivariable Analysis		
	OR	95% CI	p-value	OR	95% CI	p-value
Age (per 10-yr increase)	1.26	1.03–1.54	.027	1.24	0.97–1.59	0.090
Chemotherapy Regimen			<0.001			<0.001
Cisplatin-etoposide	1	-Reference-		1	-Reference-	
Carboplatin-paclitaxel	2.78	1.65–4.68		3.33	1.89–5.87	
Other	1.17	0.69–1.96		1.38	0.78–2.41	
Volume of lung receiving ≥20 Gy (V ₂₀)	1.02	1.00–1.04	.028	1.03	1.01–1.05	0.008
Mean lung dose	1.03	1.00–1.05	.068			NS
Male sex	1.01	0.67–1.53	.948			
Smoker	0.39	0.19–0.80	.010			
Histology			.783			
Adenocarcinoma	0.74	0.41–1.32				
Large cell	1.04	0.47–2.31				
NSCLC NOS	1.26	0.50–3.21				
Squamous	1	-Reference-				
T Stage			.562			
1	1.11	0.60–2.07				
2	0.78	0.48–1.26				
3	1.09	0.67–1.77				
4	1	-Reference-				
N Stage			.308			
0	0.45	0.17–1.14				
1	0.63	0.25–1.56				
2	0.93	0.62–1.40				
3	1	-Reference-				
Tumor location (lobe)			.746			
Lower	0.96	0.56–1.65				

Factor	Univariable Analysis			Multivariable Analysis		
	OR	95% CI	p-value	OR	95% CI	p-value
Middle	1.52	0.49–4.72				
Upper	1	-Reference-				
Neoadjuvant Chemotherapy	1.49	0.92–2.41	.106			
Adjuvant Chemotherapy	0.87	0.49–1.55	.642			
Total radiation dose	1.00	0.97–1.03	.963			
Dose per fraction	0.87	0.39–1.95	.740			
Volume of lung receiving ≥ 5 Gy (V5)	0.99	0.98–1.01	.202			

OR: odds ratio; CI: confidence interval; NSCLC: non-small cell lung cancer; NOS: not otherwise specified.

Table 4

Multivariable analysis of factors predictive of symptomatic radiation pneumonitis in the validation dataset (n=279).

Factor	Multivariable Analysis		
	OR	95% CI	p-value
Age (per 10 yr increase)	1.38	0.95–2.01	.089
Chemotherapy Regimen			<0.001
Cisplatin- Etoposide	1	-Reference-	
Carboplatin- paclitaxel	5.52	2.25–13.55	
Other	3.39	1.50–7.68	
Volume of lung receiving 20 Gy(V20)	1.07	1.03–1.11	<.001

OR: odds ratio; CI: confidence interval.

Table 5

Risk of radiation pneumonitis based on V_{20} (volume of lung receiving 20 Gy or more) in the whole cohort of patients (training and validation set combined).

Lung volume receiving 20 Gy	Symptomatic pneumonitis (% of patients)	Fatal pneumonitis (% of patients)
<20%	18.4%	0.0%
20–29.99%	30.3%	1.0%
30–39.99%	32.6%	2.9%
40%	35.9%	3.5%